- Home
- CLGN vs NRXP Comparison
CLGN vs NRXP Comparison
Compare CLGN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- NRXP
- Stock Information
- Founded
- CLGN 2004
- NRXP 2015
- Country
- CLGN Israel
- NRXP United States
- Employees
- CLGN N/A
- NRXP N/A
- Industry
- CLGN Industrial Specialties
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- NRXP Health Care
- Exchange
- CLGN Nasdaq
- NRXP Nasdaq
- Market Cap
- CLGN 37.4M
- NRXP 34.7M
- IPO Year
- CLGN N/A
- NRXP N/A
- Fundamental
- Price
- CLGN $2.58
- NRXP $2.09
- Analyst Decision
- CLGN Strong Buy
- NRXP Strong Buy
- Analyst Count
- CLGN 2
- NRXP 3
- Target Price
- CLGN $12.50
- NRXP $31.67
- AVG Volume (30 Days)
- CLGN 12.3K
- NRXP 183.5K
- Earning Date
- CLGN 03-26-2025
- NRXP 03-17-2025
- Dividend Yield
- CLGN N/A
- NRXP N/A
- EPS Growth
- CLGN N/A
- NRXP N/A
- EPS
- CLGN N/A
- NRXP N/A
- Revenue
- CLGN $515,000.00
- NRXP N/A
- Revenue This Year
- CLGN $2,474.76
- NRXP N/A
- Revenue Next Year
- CLGN $52.63
- NRXP N/A
- P/E Ratio
- CLGN N/A
- NRXP N/A
- Revenue Growth
- CLGN N/A
- NRXP N/A
- 52 Week Low
- CLGN $2.54
- NRXP $1.10
- 52 Week High
- CLGN $6.75
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CLGN 26.97
- NRXP 43.44
- Support Level
- CLGN $2.54
- NRXP $1.95
- Resistance Level
- CLGN $3.70
- NRXP $2.20
- Average True Range (ATR)
- CLGN 0.26
- NRXP 0.18
- MACD
- CLGN -0.04
- NRXP 0.02
- Stochastic Oscillator
- CLGN 3.45
- NRXP 26.09
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.